Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The corticostriatal and hippocampal circuits contribute to the neurobiological underpinnings of several neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease and schizophrenia. Based on biological function, these circuits can be clustered into motor circuits, associative/cognitive circuits and limbic circuits. Together, dysfunctions in these circuits produce the wide range of symptoms observed in related neuropsychiatric disorders. Intracellular signaling in these circuits is largely mediated through the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway with an additional role for the cyclic guanosine monophosphate (cGMP)/ protein kinase G (PKG) pathway, both of which can be regulated by phosphodiesterase inhibitors (PDE inhibitors). Through their effects on cAMP response element-binding protein (CREB) and Dopamine- and cAMP-Regulated PhosphoProtein MR 32 kDa (DARPP-32), cyclic nucleotide pathways are involved in synaptic transmission, neuron excitability, neuroplasticity and neuroprotection. In this clinical review, we provide an overview of the current clinical status, discuss the general mechanism of action of PDE inhibitors in relation to the corticostriatal and hippocampal circuits and consider several translational challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358 · cited 1×
“The ventral part appears to be involved in limbic functions, motivated behavior, neuroendocrine functions and autonomic functions, thereby regulating the impact of emotional experiences and controlling general affective states (Fanselow and Dong, 2010).”
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Transcriptional regulation by the phosphorylation-dependent factor CREB
Mayr, B., & Montminy, M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35085068 · Cited by 2,587 · cited 2×
“…postsynaptic strengthening, PKA can result in the activation of two subsequent pathways: the cAMP response element binding protein (CREB) pathway (Mayr and Montminy, 2001) and the Dopamine- and cAMP-Regulated PhosphoProtein MR 32 kDa (DARPP-32) pathway (Greengard, 2001; Svenningsson et al.,…”
Sex bias in neuroscience and biomedical research
Beery, A. K., & Zucker, I. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.07.002 · Cited by 1,763
Functional organization of the hippocampal longitudinal axis
Strange, B. A., Witter, M. P., Lein, E. S., & Moser, E. I. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3785 · Cited by 1,738 · cited 1×
“The hippocampus is also described as having a ventral and a dorsal part (in animals) or an anterior and a posterior part (in humans) with similar composition, but both supporting different functions (Strange et al., 2014).”
Surmeier, D. J., Ding, J., Day, M., Wang, Z., & Shen, W. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.008 · Cited by 1,203 · cited 1×
“Additionally, every circuit is modulated by dopamine (Surmeier et al., 2007; Surmeier et al., 2011).”
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652 · cited 1×
“As a result PDE1 inhibitors are investigated in clinical trials for their cognition enhancing potential in schizophrenic patients, as these patients are characterized (among others) by frontal dopaminergic hypofunction (Meyer-Lindenberg et al., 2002; Van Os and Kapur, 2009).”
DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling
Millar, J. K., Pickard, B. S., Mackie, S., James, R., Christie, S., Buchanan, S. R., Malloy, M. P., Chubb, J. E., Huston, E., Baillie, G. S., et al. (2005) · Science · doi:10.1126/science.1112915 · Cited by 648 · cited 2×
“The involvement of PDE4 in schizophrenia is also supported by interaction of PDE4B with Disrupted in schizophrenia 1 (DISC1) (Millar et al., 2005; Clapcote et al., 2007; Murdoch et al., 2007), which is a genetic susceptibility factor for schizophrenia (Chubb et al., 2008), and by the association of PDE4B polymorphisms…”
Cited by
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Wang, H., Xu, J., Lazarovici, P., Quirion, R., & Zheng, W. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00255 · Cited by 436
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
Wang, H., Zhang, F.-F., Xu, Y., Fu, H.-R., Wang, X.-D., Wang, L., Chen, W., Xu, X.-Y., Gao, Y.-F., Zhang, J.-G., et al. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa048 · Cited by 84
Metadata
- Authors
- Heckman, P. R. A., Blokland, A., Bollen, E. P. P., & Prickaerts, J.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 87
- Pages
- 233-254
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2788944745
- Cited by
- 74
- References
- 28
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. https://app.cochat.ai/papers/10.1016/j.neubiorev.2018.02.007
- The paper
- Heckman, P. R. A., Blokland, A., Bollen, E. P. P., & Prickaerts, J. (2018). Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. Neuroscience & Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2018.02.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.